Rapamycin Overview, Dosing & Safety | Peptide Database

Rapamycin (Sirolimus)

mTOR Inhibitor | Longevity & Immunosuppression

Community Research

Join others researching Rapamycin — share findings, ask questions, and learn from real experiences

Rapamycin (sirolimus) is a macrolide compound originally discovered in 1972 from a soil bacterium (Streptomyces hygroscopicus) found on Easter Island (Rapa Nui). It was FDA-approved in 1999 as an immunosuppressant for the prevention of organ transplant rejection and has since become the most studied pharmacological intervention for lifespan extension. Rapamycin is the only drug that has consistently extended lifespan in every organism tested, including yeast, worms, flies, and mice, making it the benchmark compound in longevity research. At immunosuppressive doses (daily administration), it prevents transplant rejection and treats certain cancers. At lower pulsed doses (weekly administration), it is increasingly used off-label in the longevity community to target aging-related pathways while minimizing immunosuppressive side effects. The distinction between daily immunosuppressive dosing and weekly pulsed longevity dosing is critical, as the side effect profiles differ substantially between these two regimens.

Rapamycin exerts its effects by binding to the intracellular protein FKBP12, forming a complex that directly and specifically inhibits mechanistic target of rapamycin complex 1 (mTORC1). mTORC1 is a master nutrient-sensing kinase that integrates signals from growth factors, amino acids, energy status, and stress to regulate cell growth, proliferation, and metabolism. When mTORC1 is active, it promotes anabolic processes including protein synthesis (via S6K1 and 4E-BP1 phosphorylation), lipid synthesis, and nucleotide synthesis while suppressing autophagy. By inhibiting mTORC1, rapamycin shifts the cellular balance from growth toward maintenance and repair: it upregulates autophagy (cellular self-cleaning), enhances mitochondrial function, reduces senescent cell accumulation, improves proteostasis, and reduces chronic low-grade inflammation (inflammaging). With chronic daily dosing, rapamycin can also inhibit mTORC2, which mediates Akt signaling and is responsible for some of the metabolic side effects (insulin resistance, lipid changes). Pulsed weekly dosing preferentially inhibits mTORC1 while allowing mTORC2 to recover between doses, which is believed to account for the improved side effect profile of longevity protocols.

Molecular Data

Research Indications

Rapamycin is the most robust pharmacological lifespan extender identified to date. The NIA Interventions Testing Program demonstrated 9-14% median lifespan extension in genetically heterogeneous mice, even when initiated late in life. These findings have been replicated across multiple independent laboratories and model organisms.

mTORC1 inhibition is the most potent pharmacological inducer of autophagy. Rapamycin promotes clearance of damaged organelles, misfolded proteins, and dysfunctional mitochondria, all of which accumulate with aging and contribute to age-related disease.

Low-dose intermittent rapamycin (e.g., 5 mg weekly for 6 weeks) improved influenza vaccine response by approximately 20% in elderly volunteers in the Mannick et al. trial. This paradoxical immune enhancement at low doses contrasts with the immunosuppression seen at high chronic doses.

FDA-approved indication for prevention of renal transplant rejection in combination with calcineurin inhibitors and corticosteroids. Daily dosing at 2-5 mg/day maintains immunosuppression to prevent graft rejection.

FDA-approved for treatment of LAM, a rare progressive lung disease. Sirolimus stabilizes lung function and reduces chylous effusions by inhibiting the dysregulated mTOR signaling that drives the disease.

The Participatory Evaluation of Aging with Rapamycin for Longevity (PEARL) trial demonstrated that topical rapamycin (applied to gums) significantly reduced periodontal inflammation and gingival immune aging markers, supporting localized anti-aging effects.

Preclinical evidence in mouse models of Alzheimer disease shows rapamycin reduces amyloid and tau pathology, improves cognitive performance, and enhances cerebrovascular function. Human trials are underway.

In aged mice, rapamycin reverses age-related cardiac hypertrophy, diastolic dysfunction, and fibrosis. The PEARL cardiac substudy and other trials are evaluating these effects in humans.

Dosing Protocols

Rapamycin is administered orally as tablets or an oral solution. Bioavailability is approximately 15% due to extensive first-pass metabolism by CYP3A4 and efflux by P-glycoprotein in the gut. Absorption is affected by food, particularly high-fat meals, which increase peak concentration but not overall exposure. For consistent pharmacokinetics, it should be taken the same way each time (consistently with or without food).

Longevity - Standard Pulsed Protocol

5-6 mg once weekly

Once weekly

Oral

Longevity - Conservative Start

1-3 mg once weekly

Longevity - Biweekly Protocol

8-10 mg every two weeks

Every 14 days

Immunosuppression - Transplant

2-5 mg daily (adjust to trough levels 4-12 ng/mL)

Daily

Protocol Variations

Multiple approaches exist - compare before choosing

Different sources recommend different protocols for this peptide. Review each approach and consider your goals, tolerance, and experience level before choosing.

Weekly Pulsed Longevity Protocol

Source: Longevity community consensus / Attia, Green, Blagosklonny

"Intermittent mTORC1 inhibition captures the geroprotective benefits of rapamycin while allowing mTORC2 recovery between doses, minimizing metabolic side effects like insulin resistance and lipid dysregulation."

The most widely adopted longevity protocol involves taking rapamycin once weekly at a dose of 5-6 mg. This approach is supported by the pharmacokinetic rationale that weekly dosing provides transient mTORC1 inhibition (the target for longevity benefits) while the 62-hour half-life allows sufficient drug clearance for mTORC2 to recover before the next dose. Most practitioners recommend cycling (e.g., 8 weeks on, 2-4 weeks off) or continuous use with regular monitoring.

Key Points

Once-weekly dosing rather than daily immunosuppressive dosing

Preferentially inhibits mTORC1 while sparing mTORC2 during washout

Significantly fewer side effects than daily transplant dosing

Does not cause clinically meaningful immunosuppression at these doses

Paradoxical immune enhancement demonstrated in elderly populations

Blood trough levels are not typically targeted (unlike transplant dosing)

Dosing Schedule

Immunosuppressive Transplant Protocol

Source: FDA-approved labeling / Transplant medicine guidelines

"Continuous daily mTOR inhibition to prevent organ transplant rejection, used as part of a multi-drug immunosuppressive regimen."

The FDA-approved transplant protocol uses daily rapamycin dosing titrated to maintain trough blood levels of 4-12 ng/mL (or 12-20 ng/mL in some protocols). This is combined with calcineurin inhibitors (tacrolimus or cyclosporine) and corticosteroids. Daily dosing results in sustained inhibition of both mTORC1 and mTORC2, which accounts for the more significant side effect profile including immunosuppression, metabolic dysregulation, and impaired wound healing.

Daily dosing with therapeutic drug monitoring (trough levels)

Inhibits both mTORC1 and mTORC2 with continuous exposure

Combined with other immunosuppressants (calcineurin inhibitors, steroids)

Full immunosuppressive effect -- increased infection and malignancy risk

Significant metabolic side effects (dyslipidemia, insulin resistance)

Impaired wound healing is a clinically important consideration

Interactions

What to Expect

Side Effects & Safety

Common Side Effects

Mouth sores / aphthous ulcers (most common, usually dose-dependent and self-limiting)

Mild lipid changes (elevated LDL cholesterol and triglycerides)

Temporary glucose elevation or mildly impaired fasting glucose

Mild gastrointestinal discomfort (nausea, loose stools)

Skin changes (mild acne, slower wound healing at injection/cut sites)

Stop Signs - Discontinue if:

Persistent fever, productive cough, or signs of serious infection

Severe or non-healing mouth ulcers unresponsive to dose reduction

Significant unexplained shortness of breath (possible pneumonitis)

Severe wound healing failure or surgical complications

Marked worsening of metabolic markers (fasting glucose consistently >126 mg/dL, triglycerides >500 mg/dL)

Contraindications

Active serious infection or immunocompromised state

Hypersensitivity to rapamycin/sirolimus or any macrolide compound

Severe hepatic impairment (rapamycin is extensively hepatically metabolized)

Planned major surgery within 2-4 weeks (impaired wound healing)

Pregnancy or breastfeeding

Concurrent use of strong CYP3A4 inhibitors without dose adjustment (ketoconazole, itraconazole, clarithromycin, grapefruit juice)

Quality Checklist

Good Signs

Pharmaceutical-grade sirolimus (Rapamune) tablets or generic equivalent with valid NDC

Proper labeling with dose strength (typically 0.5 mg, 1 mg, or 2 mg tablets), lot number, and expiration date

Obtained through a licensed pharmacy with a valid prescription

Stored at room temperature in original packaging, protected from light

Tablets are intact without discoloration, crumbling, or unusual odor

Warning Signs

Compounded rapamycin from a compounding pharmacy (variable quality depending on pharmacy)

Product stored improperly (excessive heat, humidity, or light exposure)

Tablets obtained from unverified international pharmacies

Bad Signs

Product with no verifiable manufacturer, lot number, or expiration date

Tablets that are discolored, crumbled, or have an unusual smell

Research-grade rapamycin not intended for human consumption

Product sourced from unregulated online vendors without any quality verification

Frequently Asked Questions

Is rapamycin safe to use long-term as a longevity drug?

Rapamycin has 50+ years of safety data at immunosuppressive doses, but longevity-protocol doses (5-6mg weekly) lack long-term human data. The PEARL trial shows early promise, but optimal dosing, ideal pulsing schedules, and true lifespan effects in humans remain unknown—treat as experimental.

Will rapamycin cause the same side effects as when used for transplants?

Longevity-protocol rapamycin (5-6mg weekly) causes significantly fewer side effects than immunosuppressive dosing because it spares mTORC2 during the washout period between doses. Mouth sores are common but manageable; serious immunosuppression, metabolic dysregulation, and wound healing problems are far less common at low intermittent doses.

Does rapamycin actually extend lifespan in humans, or just in mice?

Rapamycin robustly extends lifespan in every animal model tested (yeast, worms, flies, mice), but human lifespan studies don't yet exist—the longest studies run 6-12 months. The TRAVERSE dog aging study is the closest bridge to human data, showing improvement in cardiac function and mobility in middle-aged dogs.

Can I combine rapamycin with metformin for better longevity benefits?

Yes—rapamycin and metformin target complementary aging pathways (mTORC1 and AMPK respectively) and show synergistic lifespan extension in preclinical models. The combination is widely used in the longevity community, though human data confirming additive benefits is limited.

References

Landmark NIA Interventions Testing Program study demonstrating that rapamycin extended median and maximum lifespan in genetically heterogeneous mice even when started at 600 days of age (approximately 60 human years). Male lifespan increased by 9% and female lifespan by 14%, establishing rapamycin as the first pharmacological agent to reproducibly extend mammalian lifespan.

Randomized controlled trial in elderly volunteers showing that 6 weeks of low-dose mTOR inhibitor (RAD001/everolimus) treatment improved influenza vaccine response by approximately 20%. Demonstrated that mTOR inhibition can paradoxically enhance immune function in aging, challenging the notion that rapamycin is purely immunosuppressive.

Comprehensive review establishing mTOR as a central node in aging biology. Details how mTORC1 inhibition by rapamycin recapitulates many benefits of caloric restriction, including enhanced autophagy, improved stem cell function, reduced inflammation, and extended lifespan across species.

Influential opinion article arguing that the side effects observed with rapamycin in transplant patients (immunosuppression, metabolic changes) are largely artifacts of chronic daily dosing and high trough levels. Proposes that intermittent low-dose rapamycin selectively inhibits mTORC1 while sparing mTORC2, providing geroprotective benefits with minimal adverse effects.

Early results from the PEARL trial, one of the first prospective human longevity trials of rapamycin, showing that topical and systemic rapamycin reduced markers of periodontal aging and systemic inflammation in healthy older adults, providing initial clinical evidence for rapamycin as a geroprotective agent in humans.

Related Peptides

Metformin and rapamycin target complementary longevity pathways: metformin activates AMPK (energy-sensing) while rapamycin inhibits mTORC1 (nutrient-sensing). Both promote autophagy and reduce inflammation through distinct mechanisms. Preclinical data suggest additive lifespan extension when combined. Metformin may partially counteract rapamycin-induced insulin resistance via its insulin-sensitizing effects, making the combination metabolically favorable.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.